In this online CME self-learning program:
Urticaria refers to a heterogeneous group of diseases characterized by flares, which are raised areas in the dermal tissue surrounding an inflamed focal point, and the pinker, flatter wheals that present during flare resolution. There is an estimated 20% lifetime prevalence of developing some degree of urticaria, and while wheals and flares typically resolve within 24 hours, the consistent emergence of new flares in some individuals can considerably impact quality of life and contribute to: difficultly sleeping, decreased energy, depression, anxiety, and social isolation. Chronic urticaria (CU) is defined as symptoms of urticaria that are present most days of the week for longer than 6 weeks. While data on the prevalence of CU in the U.S. is not readily available, a European estimate suggests that the prevalence is approximately 0.6%, and the etiology is thought to be idiopathic in a majority of cases.
There are several gaps in the care of patients with CU. On the diagnostic side, there is some debate about the subclassifications of CU, potentially leading to variable treatment. CU can often take on a fluctuating and unpredictable pattern of recurrence that may complicate diagnosis. Several publications recommend further exploration into CU to help guide treatment decisions.
Definition of urticaria, subsets, and differential diagnosis
Pathophysiology and characteristics of CU
Concise immunology review
Complications of CU
Treatment of CU: current guidelines and up-to-date best practice
Barriers to optimal care in patients with CU
Healthcare professionals specializing in: allergy, dermatology, immunology, internal and family medicine, and those who otherwise may treat patients with CU.
This program is supported by an educational grant from Genentech.
Release Date: May 14, 2014 -- Expiration Date: May 14, 2016
Faculty: Luz Fonacier, MD, FACAII, FAAAAI
By the end of the session the participant will be able to:
ACCREDITATION FOR THIS COURSE HAS EXPIRED. YOU MAY VIEW THE PROGRAM, BUT CME / CE IS NO LONGER AVAILABLE AND NO CERTIFICATE WILL BE ISSUED.
As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review ScientiaCME.
Luz Fonacier, MD has received Research and Educational Grants from Baxter, Genentech, and Merck
Disclosures of Educational Planners: Charles Turck, PharmD is an officer and part owner of ScientiaCME, LLC.
Commercial Support Disclosure: This program is supported by an educational grant from Genentech.
*Required to view Printable PDF Version
Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.